WAVE LIFE SCIENCES LTD. Deferred Offering Costs
WAVE LIFE SCIENCES LTD. (WVE) had Deferred Offering Costs of $0 as of 2015-12-31, per its 10-K filed 2016-03-30.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2016-03-30
- 2015-12-31: Deferred Offering Costs $0.00.
- 2015-09-30: Deferred Offering Costs $1.74M.
- 2014-12-31: Deferred Offering Costs $72.00K.
| Period end | Deferred Offering Costs |
|---|---|
| 2015-12-31 | $0.00 10-K · filed 2016-03-30 |
| 2015-09-30 | $1.74M 10-Q · filed 2015-12-17 |
| 2014-12-31 | $72.00K 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |